Found 151 clinical trials
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the
- 10 views
- 21 Jan, 2021
- 38 locations
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients 60 Years in Deep Molecular Response
(Tasigna), or Dasatinib (Sprycel) will be given intermittently at the same daily dose that was given daily at the time of the enrollment . Chronic phase Ph+ CML patients in stable major molecular response
- 3 views
- 31 Jul, 2021
- 1 location
DC Vaccination in CML
residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included
- 6 views
- 16 Aug, 2021
- 2 locations
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the
- 0 views
- 18 Aug, 2021
- 5 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.
- 11 views
- 07 Nov, 2020
- 1 location
Treatment Modification Based on Early Assessment of CML Patients
The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment
- 5 views
- 08 Nov, 2020
- 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia
- 38 views
- 11 May, 2021
- 442 locations
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs
- 10 views
- 07 Nov, 2020
- 1 location
Dasatinib Holiday for Improved Tolerability
Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase
- 11 views
- 05 Feb, 2021
- 80 locations
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy
- 8 views
- 07 Nov, 2020
- 1 location